ReviewRegenerative biomaterials2025
Fabrication of collagen-based biomaterials for sports medicine application.
Review in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the principal constituent of the extracellular matrix, collagen exhibits significant therapeutic potential in sports medicine, owing to its distinct triple-helical configuration and inherent biocompatibility. This biomaterial serves as a foundational material for scaffolds, membranes, patches and dressings targeting tendon repair, cartilage reconstruction and bone defect remediation. However, its clinical translation was hampered by limitations: poor tensile strength risks mechanical failure under load, immunogenicity from residual epitopes can trigger adverse reactions and rapid enzymatic degradation compromises structural integrity before tissue maturation. This review elucidates current properties and resources of collagen-based biomaterial and critically analyzes its inherent limitations and their clinical consequences. It emphasizes how evolving tissue engineering strategies directly mitigate barriers. Molecular crosslinking and chemical modification are employed to enhance tensile properties and delay degradation, critical for mechanically demanding environments. Composite blending with polymers compensates for mechanical weakness while retaining bioactivity. Advanced processing techniques such as 3D printing and electrospinning enable precise fiber alignment, replicating native tissue anisotropy and improving functional outcomes. Rigorous decellularization protocols further mitigate immunogenicity. This review further examines recent preclinical and clinical progress in collagen-based biomaterials for tendon, ligament, cartilage and bone regeneration, highlighting successful translations and ongoing challenges. Future directions focus on refining these strategies to accelerate the development of next-generation, clinically robust collagen therapies for sports medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.